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Osteoprotegerin in juvenile rheumatoid arthritis: cross talk between the 
immune and the skeletal systems 
INTRODUCTION 
Rheumatoid arthritis (RA) is the prototype of 
autoimmune diseases that links the immune system 
with bone and cartilage metabolism 1. The effects of 
rheumatoid arthritis on bone include structural joint 
damage (erosions) and osteoporosis, which are 
associated with increased morbidity and mortality. 
Osteoporosis in rheumatoid arthritis is characterized 
by a complexity of risk factors, including primary 
osteoporosis risk factors in addition to 
inflammation, immobilization, and the use of 
corticosteroids 2. 
Original article 
Background:  Previous studies have linked the decreased local production 
of osteoprotegerin (OPG), an osteoclastogenesis blocking agent, in the 
inflamed joints of rheumatoid arthritis patients to the development of bone 
erosion. 
Objective: We sought to assess OPG expression in juvenile rheumatoid 
arthritis (JRA) and to determine its relation to clinical and laboratory 
markers of disease activity, and radiologic evidence of bone resorption, as 
well as its relation to the type of onset, duration of illness and different 
therapeutic modalities.  
Methods: The study included 40 children and adolescents with JRA, as well 
as, 20 clinically healthy age- and sex- matched subjects for comparison. The 
patients underwent clinical evaluation for disease activity by the summed 
joint index and investigations including assessment of ESR, CRP, 
antinuclear antibodies and rheumatoid factor. were Serum levels of 
osteoprotegerin were assayed by ELISA in the patient and control groups. 
Joints were evaluated radiologically  using the modified Larsen index (LI). 
Results: The serum levels of OPG in the patients [ median (interquartile 
range): 0.474 (0.4) ng/ml] were comparable to those of  the control group 
[0.495 (0.41) ng/ml] (p=0.29). However, patients with pauciarticular onset 
JRA had  significantly lower OPG levels [0.3 (0.23) ng/ml] than the control 
group (p= 0.007). The OPG levels were below the 5th percentile of the 
control value in 60% of pauciarticular and 16.7% of polyarticular JRA 
cases. Patients with polyarticular JRA had significantly higher values of 
ESR, activity score and Larsen indices as well as serum OPG levels (p= 
0.001, 0.001, 0.002 and 0.02, respectively). OPG levels did not correlate to 
the ESR or the activity score index values. On the other hand, the duration 
of illness showed a tendency to be negatively correlated to serum OPG (r= -
0.309, p=0.05). LI correlated positively to the activity score index and to the 
ESR in the JRA patients, whether compiled in one group or classified into 
subgroups according to disease onset. However, OPG was not significantly 
correlated to the LI (r= 0.023). The different modalities of therapy did not 
seem to influence the serum levels of OPG (χ2 = 4.21). 
Conclusion: Serum OPG expression was low in JRA, especially in the 
pauciarticular variety. OPG levels were higher in polyarticular JRA, but 
this does not necessarily have a protective effect since the proinflammatory 
process is known to promote also the expression of RANKL, an 
osteoclastogenesis enhancer. While clinical and biochemical parameters of 
activity, and LI did not correlate to OPG, the latter seemed to be adversely 
affected by increased disease duration.  
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It has long been hypothesized that 
proinflammatory cytokines excessively produced in 
areas of active inflammation may transfer signals 
from immune cells to osteoclasts, however, the 
cellular and molecular context of this process 
remain elusive 1. Recent evidence from 
experimental arthritis and progress in understanding 
the biology of osteoclasts has shed new light on the 
pathogenesis of skeletal manifestations 3. 
Because osteoblast- stromal cell interactions 
with osteoclast precursors are required for 
subsequent osteoclast differentiation, an osteoclast 
differentiation factor expressed by these cells and 
recognized by osteoclast precursors was suspected. 
Such factor was identified as RANKL, receptor 
activator of nuclear factor -κB ligand. RANKL, a 
member of the tumor necrosis factor (TNF) ligand 
superfamily, is a transmembrane protein expressed 
in various cells and particularly on osteoblalst and 
activated T cells. RANKL can be cleaved and the 
soluble form is also active 4. Both forms of RANKL 
act through binding to and activating receptor 
activator of nuclear factor (NF)-κB (RANK), a cell-
bound receptor of the TNF receptor (TNFR) 
superfamily that is located on osteoclast precursor 
cells, mature osteoclasts, and dendritic cells. 
Following binding to its receptor, RANKL 
promotes osteoclast formation and activation, and 
inhibits osteoclast apoptosis 5.  
The potent stimulatory effects of RANK by 
RANKL are counterbalanced by an endogenous 
antagonist, osteoprotegerin (OPG). Osteoprotegerin 
is a member of the TNF receptor family that lacks a 
transmembrane domain and represents a secreted 
receptor. Osteoprotegerin (Latin: os, bone; 
protegere, to protect) recognizes RANKL, and this 
decoy receptor blocks the interaction between 
RANK and RANKL. Osteoprotegerin has been 
observed to completely antagonize the effects 
induced by RANKL both in vitro and in vivo, 
leading to inhibition of osteoclast differentiation 
and activation 6. Overexpression or exogenous 
administration of OPG have been shown to increase 
bone mass and prevent bone loss 7,8,9.  
Several lines of evidence indicate that RANK/ 
RANKL/ OPG system is essential for bone 
metabolism, plays a critical role in the orderly 
development and function of the immune system, 
and may represent a molecular link between the 
immune system and bone metabolism 1. The 
parallel roles of RANKL and OPG in regulating 
bone metabolism and the immune system may 
represent a potential therapeutic target in pathologic 
processes that are characterized by excessive bone 
resorption 6. 
This study was aimed to assess OPG levels in 
sera of patients with juvenile rheumatoid arthritis 
(JRA) in comparison to healthy individuals and to 
determine its relation to markers of disease activity, 
whether clinical or laboratory, and to radiologic 
evidence of bone resorption, as well as its relation 
to the different types of disease onset, duration of 
illness and different therapeutic modalities.  
  
METHODS 
This study was carried out at the Pediatric Allergy 
and Immunology Unit of Children’s Hospital of Ain 
Shams University in Cairo. The study was approved 
by the local ethical committee and consents were 
taken from the parents or care-givers before 
inclusion in the study.  
The study was conducted on 40 children and 
adolescents with juvenile rheumatoid arthritis 
(JRA), all of them fulfilling the American College 
of Rheumatology criteria for diagnosis of JRA 10. 
They were twenty-eight females (70%) and twelve 
males (30%), their ages ranged between 7 and 16 
years with a median (interquartile range) of 13.0 
(5.0) years. 
Patients were subdivided into: 
i- Polyarticular onset JRA: This group included 
30 children (20 females and 10 males). 
ii- Pauciarticular onset JRA: This group comprised 
10 children (8 females and 2 males),     
For comparison of results, a group of 20 age- 
and sex- matched clinically healthy children 
[median age (interquartile range): 12.56 (6.00) 
years] were included in the study. 
The following was done for the enrolled patients: 
I-Clinical evaluation: Stress was laid on the 
duration of illness, type of disease onset, number of 
affected joints, activity of arthritis, systemic 
manifestations and medications received.  
Patients were assessed for clinical parameters 
of joint inflammation (activity score) using the 
summed joint index score 11,12. For each of the 
clinical indices (the joint swelling, the pain on 
motion/joint tenderness and limitation of motion), 
the total articular activity for each patient was 
calculated, considering the affected joints only, as 
follows:  
 
Activity score = 
 joints. affected of Number
 joints. affected the of indices clinical the of Sum  
 
 
II- Laboratory evaluation: 
All participating individuals were subjected to the 
following investigations:  
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Sampling:  
1. A sample on EDTA for measurement of ESR.  
2. Clotted samples, the obtained serum was divided 
into portions, for the assay of CRP, Rheumatoid 
factor (RF) and antinuclear antibodies (ANA). A 
sample was stored at -20°C until assay of 
Osteoprotegerin level (OPG).  
Analytical Methods:  
- Erythrocyte sedimentation rate assessment 
using the Westergren method. 
- Quantitative CRP assay by direct latex 
agglutination (QUIMICA CLINICA APLICADA, 
Spain). 
- Rheumatoid factor (RF) assay by latex 
agglutination slide test (BIOTEC laboratories, 
UK) 
- Antinuclear antibodies (ANA) using indirect 
immunofluorescence method (IMMCO diagnosis, 
NY, USA) 
- Osteoprotegerin level using enzyme- linked 
immunosorbent assay (ELISA) method 
(Biovendor laboratories, Czech Republic). 
Assay procedure: Diluted standards, quality 
controls and serum samples were added to 
microplate wells coated with capture monoclonal 
antiosteoprotegerin antibody. After incubation and 
washing steps, biotin- labeled polyclonal antihuman 
osteoprotegerin antibody solution was added for a 
further incubation step. Following a final washing 
step, hydrogen peroxide tetramethylbenzidine was 
incubated into the wells resulting in a coloured 
product. After the addition of oxidic stop solution, 
the colour was measured at 450 nm. The 
absorbance and colour intensity were considered 
proportional to the concentration of OPG in the 
sample. A standard curve was constructed and the 
concentration of OPG in the samples was 
determined 13.  
III- Radiographic evaluation: 
X- ray films were taken at the time of sampling. 
Evaluation was done according to modified Larsen 
scoring methods 14. Joints examined radiologically 
were those of the hands, feet and knees. A mean 
value score of all joints was obtained for each 
patient (Larsen Index). 
 
Statistical methods: 
Statistical analysis was done using a software 
package (SPSS) version 10.0. Quantitative 
nonparametric variables were presented as median 
(interquartile range). Comparison between the 
different studied variables was done using Mann-
Whitney U test. Correlation of different numerical 
variables was attempted using Spearman r 
correlation test. From statistical tables, the 
probability (p) value were calculated, p values less 
than 0.05 were considered significant. A cut-off 
value for OPG corresponding to the 5th percentile 
of the control group was calculated (equals 0.348 




This study was conducted on 40 patients with JRA, 
their median age (interquartile range) was 13.0 (5.0) 
years. Thirty of the included patients had 
polyarticular onset JRA (median age 13.5 (4.63) 
years), while ten patients had pauciarticular onset 
JRA (median age of 12.0 (5.76) years. The duration 
of disease ranged between 1 and 11 years [median 
(interquartile range): 5.25 (4.0) years] (Details of 
the clinical characteristics of the included patients 
are summarized in Table 1).  
The serum levels of OPG in our patients were 
lower than, though not significantly different from, 
that of the control group [median (interquartile 
range): 0.474 (0.4) and 0.495 (0.41) ng/ml, 
respectively] (z=1.05, p=0.29). However, when 
comparing subgroups of JRA patients (those with 
polyarticular and those with pauciarticular onset 
JRA) to the control group, we found that patients 
with pauciarticular onset JRA had significantly 
lower OPG levels [median (interquartile rang): 0.3 
(0.23) ng/ml] than the control values (z= 2.65, p= 
0.022) (Figure 1). 
With a cut off value of 0.348 ng/ml, 60% of 
patients with pauciarticular JRA had OPG values 
below the 5th percentile of the control group, a 
result that is significantly different from that of 
patients with polyarticular JRA (16.7% only) 
(χ2=7.06, p=0.014) (Figure 2).  
Trying to evaluate the relation of OPG to 
disease activity, we correlated its levels with that of 
ESR and activity score index, but found no 
significant correlation (r= 0.071 and –0.03, 
respectively). Similarly, CRP positivity did not 
affect the serum levels of OPG (z= 0.03). The 
median Larsen index (LI) was 1.5 (1.9) (ranging 
between 0.33 and 4.33). Whether in the patients 
group or in either of the polyarticular or the 
pauciarticular patients subgroups, it was noted that 
LI had a significant positive correlation to the 
activity score index (r= 0.98, 0.98 and 0.87, 
respectively and p= 0.0001, 0.0001 and 0.001, 
respectively) and to the ESR ( r= 0.96, 0.97 and 
0.91, respectively and p= 0.0001). However, OPG 
did not show a significant correlation to LI (r= 
0.023). 
Comparing patients with polyarticular and 
those with pauciarticular onset- JRA, we found that 
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patients with polyarticular JRA had significantly 
higher ESR values, activity score and Larsen 
indices compared to pauciarticular patients. 
Furthermore, serum OPG levels were significantly 
higher in the polyarticular group than in 
pauciarticular- onset JRA (Table 2).   
Comparing the OPG levels in different 
subgroups of polyarticular onset JRA, we found no 
significant difference when comparing patients with 
RF positive-, ANA positive- and seronegative- 
polyarticular JRA with each other [median 
(interquartile rang): 0.62 (0.47), 0.47 (0.29) and 
0.47 (0.34) ng/ml, respectively].  
The duration of illness showed a tendency to be 
negatively correlated to serum levels of OPG 
meaning that the longer the duration of illness was, 
the lower got the levels of OPG (r= -0.309, p=0.05). 
Comparing patients only on nonsteroidal anti-
inflammatory drugs to those receiving 
immunosuppressive agents did not reveal 
significant difference in their OPG levels (z= 1.706, 
p=0.09). Similarly, patients on steroids and those 
receiving methotrexate had OPG levels comparable 
to those not receiving such drugs(z=1.25 and 0.015, 












































Figure (1): Comparison between osteoprotegerin 











Figure (2): Variation of osteoprotegerin expression with the type of JRA onset 
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Table (1): Some clinical and laboratory data of the JRA patients  
Age    in years 
           Median (interquartile range) 
 
13.0 (5.0) 
Subgroups of JRA           [number (%)] 
          Polyarticular JRA 
                   RF- positive  
                   ANA- positive 
                   Seronegative 
           Pauciarticular JRA  
                    RF- negative 
                    ANA-positive       
 
30  
6 (20%)  




 8 (80%) 
Duration of disease  in years 
           Median (interquartile range) 
 
5.25 (4.0) 
Therapeutic modalities     [number (%)]  
          NSAIDs only 
           Steroids Use  





Summed joint index score 
           Range 




Laboratory markers of disease activity  
            ESR  in mm/h 
                  Range 
                  Median (interquartile range)               





11 (27.5%)  
ANA: antinuclear antibodies; ESR: erythrocyte sedimentation rate; CRP: C-reactive 
protein; JRA: juvenile rheumatoid arthritis; NSAIDs: nonsteroidal anti-inflammatory 
drugs; RF: rheumatoid factor.  
 
Table (2): Variation of some studied parameters according to type of JRA onset  
Parameters evaluated 






ESR (mm/hr) 20.0 (37.5) 5 .0 (5.0) 3.36** 
Activity score 6.0 (6.38) 3 (0.8) 3.19** 
LI 1.83 (1.83) 1.0 (4.17) 3.03** 
Serum OPG(ng/ml) 0.5 (0.39) 0.3 (0.23) 2.28* 
*p< 0.05, **p< 0.01 
ESR: erythrocyte sedimentation rate; JRA: juvenile rheumatoid arthritis; LI: Larsen index; OPG: osteoprotegerin. 
 
DISCUSSION 
The pathogenesis of bone loss in rheumatoid 
arthritis is multifactorial; disease activity certainly 
is a major determinant of bone mass. Further 
pathogenic factors include effects of anti-
inflammatory therapies (in particular 
glucocorticoids), reduced mobility, estrogen and/or 
androgen deficiency 15. 
In our series, radiologic evidence of bone 
resorption was found to correlate to clinical and/or 
biochemical markers of disease activity of the JRA 
patients, whether compiled in one group or 
classified into polyarticular  and pauciarticular 
subgroups. It has been previously reported that 
bone loss correlates well with measures of 
inflammation 16,6 and that proinflammatory 
cytokines as IL-1 and TNF-α are among factors 
triggering excessive osteoclastic activity, though 
the underlying mechanism was not completely 
understood. Recently it has been  demonstrated that 
osteotropic factors and hormones such as PTH, 
1,25(OH)2D3, IL-1, IL-1β, TNF-α or prostaglandin 
E2 act though a common pathway up regulating 
RANKL expression in osteoblast/stromal cells. By 
binding to its receptor (RANK) on osteoclasts 
precursors, RANKL promotes their differentiation 
and activation into mature osteoclasts 6 . 
The RANK/ RANKL system is completed by 
OPG that recognizes and blocks the interaction of 
RANKL. Measuring its levels in the enrolled 
patients, we found that values of OPG were lower 
than those of the control group, most evident in the 
pauciarticular JRA group. Furthermore, 60% of 
patients with pauciarticular JRA had serum OPG 
values below the 5th percentile of the control group. 
Osteoprotegerin in JRA. 
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To our knowledge, this is the first study 
assessing OPG levels in pediatric patients with 
JRA. Our results are supported by the findings of 
Takayanagi et al. 17 and Wong et al. 18 who reported 
that synovial fluid from adult patients with RA 
contained lower OPG levels compared to patients 
with other joint diseases, indicating a relative 
decrease of local production of OPG to compensate 
for the up-regulated RANKL expression seen in 
those patients. Similarly, Haynes et al. 19 reported 
that OPG expression on macrophage type synovial 
lining cells as well as on endothelial cells is 
deficient in RA patients with active synovitis, in 
contrast to that seen in patients with other joint 
diseases (spondyloarthropathy and osteoarthritis) or 
in healthy subjects. They suggested that this 
deficiency in OPG expression in the inflamed joints 
of RA patients may be important in the 
development of radiologically defined joint 
erosions. In support of these findings are the results 
of Wong et al. 18 who noted that IFN-α treatment 
of RA synovial fluid cells resulted in upregulation 
of OPG gene expression of those cells. 
     Comparing patients with polyarticular and 
those with pauciarticular JRA, we found a 
significantly higher clinical and biochemical 
markers of disease activity and higher OPG levels 
in patients with polyarticular compared to those 
with pauciarticular onset- JRA. The difference in 
the results of both groups can be explained by the 
underlying immunopathogenic mechanism of the 
polyarticular JRA which is characterized by 
proinflammatory response and manifested by 
increased proinflammatory cytokines 20 . In their 
study, Ziolkowska et al. 21 and Rifas et al. 22  stated 
that the proinflammatory cytokines enhance OPG 
and RANKL production in RA patients but the 
OPG:RANKL ratio is rather fixed or even 
decreased in view of the essentially lower OPG 
concentration in RA patients than controls. Recent 
studies have demonstrated that the control of 
osteoclastic differentiation, activity and survival 
and hence, bone resorption in the 
OPG/RANK/RANKL system resides, not in the 
absolute quantities of either OPG or RANKL, but 
rather in the proportion of the inhibitory OPG to the 
stimulatory RANKL 23,24 , which may explain why 
the higher levels of OPG in patients with 
polyarticular JRA did not have a protective effect 
against bone resorption. By comparison, the 
immunopathogenic mechanism underlying 
pauciarticular JRA is an anti-inflammatory response 
manifested by increased IL-4 and IL-10 mRNA 20 . 
Studies showed that IL-4 suppresses RANKL 
mRNA expression, even more, suppresses type I 
collagen breakdown, which may well explain the 
difference seen in our study between patients with 
polyarticular and those with pauciarticular onset 
JRA 25. 
Correlating OPG levels to markers of disease 
activity, we found no significant  
correlation to either laboratory or clinical 
markers of disease activity. This result is similar to 
that of Valleala et al. 26 and Feuerham et al. 13 who 
could not detect any relation between the disease 
activity and levels of OPG. Though most 
proinflammatory cytokines (IL-1, IL-11, IL-17 and 
TNF-α) are known to increase the levels of OPG 
and RANKL, others (IL-6 and IL-7) have no effect 
on OPG levels 23. Furthermore, basic fibroblast 
growth factor (bFGF) inhibits OPG production by 
human fibroblast- like synovial cells by negating 
the direct stimulatory effect of the inflammatory 
cytokines in a dose- dependent manner 27.   
Levels of OPG in our series did not 
significantly correlate to radiologic evidence of 
bone erosion (LI). Similar to our findings are those 
of Valleala et al. 26 who found no significant 
correlation between serum OPG levels and 
radiologic evidence of disease progression or even 
biochemical markers of bone metabolism. The 
complex interplay of cytokines in the regulation of 
the RANK/ RANKL/ OPG system may be a 
possible cause of this non significant relation. Also, 
none of the evidence so far excluded the possibility 
that other cells other than osteoclasts contribute to 
bone resorption. For example, the production of 
matrix metalloproteinases by the macrophages and 
synovial fibroblasts may directly increase bone 
erosion and play a role in preparation of bone 
surfaces for osteoclast attachment 28 . 
The duration of illness showed a tendency to be 
negatively correlated to the level of OPG, it seems 
that longer exposure to proinflammatory cytokines, 
has a suppressant effect on OPG production. We 
could not trace similar data in the literature to 
compare our results. 
It has been proposed that glucocorticoids  29,30 
and immunosuppressants 31 support osteoblastic 
bone resorption by increasing the levels of RANKL 
and reducing OPG expression 23; nevertheless, the 
different modalities of therapy did not seem to 
affect the level of OPG in our study. Valleala et al. 
26 in their study on patients with RA stated that , at 
least, low dose corticosteroids- associated 
osteoporosis is probably not mediated through 
inhibition of OPG. Another plausible explanation is 
that the suppressant effect of the corticosteroids and 
immunosuppressant drugs on the inflammatory 
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process may play a role in antagonizing their direct 
action on the OPG/RANKL system. 
In conclusion, serum OPG levels are lowered in 
patients with JRA, especially so in patients with 
pauciarticular JRA. While OPG levels were higher 
in patients with polyarticular than in those with 
pauciarticular JRA, this did not seem to have a 
protective effect on bone resorption since the 
proinflammatory process is known to equally 
promote higher levels of OPG and RANKL 
expression. While parameters of disease activity, 
whether clinical or biochemical, and degree of bone 
resorption did not show a significant correlation to 
OPG, its levels seem to be adversely affected by the 
increased duration of the disease. Steroids and 
immunosuppressive drugs did not seem to affect 
OPG levels and thus the known osteoporotic effect 
of these drugs may be mediated by other 
mechanisms.  
Demonstration of the role of the newly 
discovered RANK/RANKL/OPG system provides 
hope that specific therapy can be provided for 
preventing bone loss and joint destruction. The 
primary consideration for the use of exogenous 
OPG to treat RA is that control of osteoclastic 
network depends on the ratio of OPG: RANKL. 
Thus, strategies that enhance local production of 
IL-4 or neutralize IL-1 and TNF-α  together with 
OPG administration have been suggested. This may 
not only decrease bone loss but also inhibit the 
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